Both experiences (initial fog, subsequent clarity) are plausible and can be explained mechanistically.
Initial brain fog (weeks 1-3):
- Rapid caloric reduction can temporarily reduce glucose availability to the brain
- GI side effects (nausea, disrupted eating patterns) may cause mild dehydration, which impairs cognition
- Any significant pharmacological change can cause an adjustment period in neurotransmitter systems
Subsequent clarity (weeks 3+):
- GLP-1 receptors are expressed in the hippocampus (memory and learning center). Preclinical studies show GLP-1 RA activation in the hippocampus enhances synaptic plasticity and may improve learning.1
- Reduced systemic inflammation (which GLP-1 RAs are shown to do) directly benefits cognitive function — neuroinflammation is a significant contributor to brain fog2
- Improved insulin sensitivity means better glucose regulation in the brain — the brain is exquisitely sensitive to glucose fluctuations
- Better sleep quality (due to reduced sleep apnea, less nighttime eating, improved metabolic health) has profound cognitive effects
- The "freed bandwidth" effect Carla described is real — cognitive load theory tells us that obsessive thought loops consume working memory resources
There are actually clinical trials underway investigating semaglutide for Alzheimer's disease and cognitive decline, based on the neuroprotective properties of GLP-1 receptor activation.3
1 During et al., "GLP-1 receptor is involved in learning and neuroprotection," Nature Medicine, 2003.
2 Boccardi et al., "The potential role of GLP-1 RAs in the treatment of neurodegeneration," Frontiers in Neuroscience, 2019.
3 ClinicalTrials.gov: NCT04777396 — Semaglutide in Early Alzheimer's Disease (EVOKE).